Envista price to free cash flow NVST
Market value divided by free cash flow over the last twelve months, since 2020.
- Today, Nov 2, 2026
- 16.0×
- 6-year median
- 19.1×
- Against its 6-year history
- 33rd
- percentile: 0 is its lowest day, 100 its highest
- 6-year range
- 8.6× to 62.4×
- Peer median
- 24.8×
Envista's price to free cash flow is 16.0× as of Nov 2, 2026.
That is below its 6-year median of 19.1×, lower than on 67% of days in the last 6 years.
Over that time it ranged from 8.6× in Apr 2025 to 62.4× in Mar 2023.
The median for 10 medical instruments and supplies stocks of a similar size is 24.8×.
Price to free cash flow over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 16.0× | 13.6× | 20.8× |
| 2025 | 13.8× | 8.6× | 14.0× |
| 2024 | 12.1× | 9.7× | 19.2× |
| 2023 | 19.0× | 17.0× | 62.4× |
| 2022 | 39.0× | 19.0× | 44.0× |
| 2021 | 20.2× | 14.7× | 29.9× |
| 2020 | 23.7× | 18.6× | 25.9× |
Against its peers
Companies in Medical - Instruments & Supplies nearest Envista's size, closest first, today.
| Company | Price to free cash flow |
|---|---|
| NVSTEnvista | 16.0× |
| ICUIICU Medical | 26.6× |
| BMIBadger Meter | 31.6× |
| VNTVontier | 12.9× |
| MMSIMerit Medical Systems | 24.8× |
| ATRCAtriCure | 57.3× |
| WRBYWarby Parker | 136× |
| HAEHaemonetics | 18.8× |
| UFPTUFP Technologies | n/m |
| MSAMSA Safety | 20.3× |
| INSPInspire Medical Systems | 16.6× |
| Peer median | 24.8× |
What the price to free cash flow tells you
Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.
Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.
More on Envista
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.